ATE67504T1 - Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten. - Google Patents

Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten.

Info

Publication number
ATE67504T1
ATE67504T1 AT86300894T AT86300894T ATE67504T1 AT E67504 T1 ATE67504 T1 AT E67504T1 AT 86300894 T AT86300894 T AT 86300894T AT 86300894 T AT86300894 T AT 86300894T AT E67504 T1 ATE67504 T1 AT E67504T1
Authority
AT
Austria
Prior art keywords
insulin receptor
production
antibodies
dna
purification
Prior art date
Application number
AT86300894T
Other languages
English (en)
Inventor
John Richard Bell
Axel Ulrich
Janakiraman Ramachandran
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE67504T1 publication Critical patent/ATE67504T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT86300894T 1985-02-12 1986-02-10 Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten. ATE67504T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/700,776 US4761371A (en) 1985-02-12 1985-02-12 Insulin receptor
EP86300894A EP0192392B1 (de) 1985-02-12 1986-02-10 Insulin-Receptor, seine Reinigung, seine Herstellung in rekombinanten Zellen, DNA hierfür, Antikörper gegen den Insulin-Receptor und deren Herstellung, sowie pharmazeutische Zusammensetzungen, die diese Antikörper enthalten

Publications (1)

Publication Number Publication Date
ATE67504T1 true ATE67504T1 (de) 1991-10-15

Family

ID=24814821

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86300894T ATE67504T1 (de) 1985-02-12 1986-02-10 Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten.

Country Status (6)

Country Link
US (1) US4761371A (de)
EP (1) EP0192392B1 (de)
JP (1) JPH074249B2 (de)
AT (1) ATE67504T1 (de)
CA (1) CA1341149C (de)
DE (1) DE3681466D1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US5981481A (en) * 1974-12-06 1999-11-09 The Johns Hopkins University Human C3b/C4b receptor (CR1)
US5985587A (en) * 1984-08-17 1999-11-16 The Scripps Research Institute Polypeptide-induced monoclonal receptors to protein ligands
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
AU7481087A (en) * 1986-05-09 1987-12-01 Biotechnoloty Research Associates J.V. Atrial natriuretic peptide receptor protein and its encoding dna
US6673896B1 (en) * 1986-08-21 2004-01-06 The Trustees Of Columbia University In The City Of New York Derivatives of soluble T-4
AU616639B2 (en) 1986-08-21 1991-11-07 Trustees Of Columbia University In The City Of New York, The Dna encoding the t cell surface protein t4 and use of fragments of t4 in the treatment of aids
US5126433A (en) * 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US5958678A (en) * 1986-08-21 1999-09-28 The Trustees Of Columbia University In The City Of New York DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
AT391998B (de) * 1987-02-02 1990-12-27 Falko Dr Skrabal Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen
US5688763A (en) * 1987-06-12 1997-11-18 Hammonds, Jr.; R. Glenn Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
IL83687A (en) * 1987-08-30 1995-03-30 Yeda Res & Dev Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US4962155A (en) * 1987-12-07 1990-10-09 City Of Hope Methods and compositions for activating the human insulin receptor kinase
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6180368B1 (en) * 1988-03-23 2001-01-30 University Of Melbourne Ryegrass pollen allergen
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
WO1989010939A1 (en) * 1988-05-13 1989-11-16 University Patents, Inc. Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens
US5227466A (en) * 1988-06-30 1993-07-13 City Of Hope Insulin receptor binding site
JPH03501487A (ja) * 1988-06-30 1991-04-04 シティ・オブ・ホープ インシュリン模倣物およびインシュリンリセプター結合部位ペプチド
EP0364690A3 (de) 1988-08-23 1990-07-18 Dana Farber Cancer Institute Alpha-Subeinheit des Mac-1-Leukocyt-Adhäsions-Rezeptors
US5880260A (en) 1988-11-18 1999-03-09 Oregon Health Sciences University Dopamine receptors and genes
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
EP1201757A3 (de) * 1988-12-22 2002-09-11 Genentech, Inc. Verfahren zur Herstellung von wasserlöslichen Polypeptiden
ES2068388T3 (es) * 1989-05-05 1995-04-16 Genentech Inc Moleculas de receptor de hormona de la glucoproteina.
US6261800B1 (en) 1989-05-05 2001-07-17 Genentech, Inc. Luteinizing hormone/choriogonadotropin (LH/CG) receptor
US5073540A (en) * 1989-05-15 1991-12-17 Receptron Composite binding site drugs
CA2055441C (en) * 1989-05-19 2003-01-07 Robert M. Hudziak Her2 extracellular domain
HU215581B (hu) * 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US6203976B1 (en) * 1989-07-18 2001-03-20 Osi Pharmaceuticals, Inc. Methods of preparing compositions comprising chemicals capable of transcriptional modulation
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
ATE238431T1 (de) * 1989-07-18 2003-05-15 Osi Pharm Inc Methode der veränderung der expression von genen bei der transkription und zum nachweis von chemischen substanzen, die wie modulatoren der genexpression wirken
US5215963A (en) * 1989-10-24 1993-06-01 Berlex Laboratories, Inc. Solubilization and purification of the active gastrin releasing peptide receptor
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US6265566B1 (en) 1990-08-17 2001-07-24 Immulogic Pharmaceuticals, Inc. Ryegrass pollen allergen
US5569601A (en) 1990-12-07 1996-10-29 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Human dopamine receptor and its uses
AU1469292A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
WO1992013091A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
DK0575357T3 (da) 1991-03-15 2002-11-25 Applied Research Systems Human receptor for follikelstimulerende hormon
CA2122359A1 (en) 1991-11-01 1993-05-13 Massimo Pietropaolo Antigen associated with type i diabetes mellitus
US5532347A (en) * 1992-04-10 1996-07-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization DNA encoding α melanocyte stimulating hormone receptor
US5280112A (en) * 1992-04-10 1994-01-18 State Of Oregon, Oregon Health Sciences University DNA sequence encoding bovine and human adrenocorticotropic hormone receptors
AU1812595A (en) * 1994-02-28 1995-09-11 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Cell lines for the identification of substances affecting insulin receptor mediated signal transduction
WO1995030775A1 (en) * 1994-05-06 1995-11-16 Nexstar Pharmaceuticals, Inc. High-affinity ligands of insulin receptor antibodies, tachykinin substance p, hiv integrase and hiv-1 reverse transcriptase
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
CA2364305A1 (en) 1999-03-31 2000-10-05 The University Of North Carolina At Chapel Hill Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same
US6911314B2 (en) 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme
WO2000073793A2 (en) 1999-05-27 2000-12-07 Cecil Yip Identification of compounds modulating insulin receptor activity
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
GB9924717D0 (en) * 1999-10-19 1999-12-22 Glaxo Group Ltd Diagnostic
EP2305312B1 (de) 2001-10-10 2015-03-04 ratiopharm GmbH Neumodulierung und Glykokonjugation von Follitropin (FSH)
CN102212019B (zh) 2003-03-14 2015-05-27 蔚所番有限公司 支化水溶性聚合物及其缀合物
EP1615945B1 (de) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
US7514593B2 (en) 2003-05-30 2009-04-07 The University Of North Carolina At Chapel Hill Animal model for chronic obstructive pulmonary disease and cystic fibrosis
EP1751115A4 (de) 2004-05-23 2010-10-20 Gerard M Housey Theramuteinmodulatoren
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
US8431110B2 (en) * 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
WO2007062213A2 (en) * 2005-11-23 2007-05-31 Housey Pharmaceuticals Inc Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
PL1969127T5 (pl) 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
EP2395021A1 (de) 2006-06-06 2011-12-14 Oleg Iliich Epshtein Medizinisches Mittel zur Behandlung von Fettsucht, Diabetes und Erkrankungen im Zusammenhang mit beeinträchtigter Glucosetoleranz
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20080070251A1 (en) * 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
AU2008245524A1 (en) 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
JP5851410B2 (ja) 2009-10-30 2016-02-03 シーエヌジェイ ホールディングス、インク． 組換えビタミンｋ依存性タンパク質の生成法
JP2015536148A (ja) 2012-11-20 2015-12-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変第ｉｘ因子タンパク質についての方法および組成物
AU2016215124B2 (en) 2015-02-06 2020-08-06 The University Of North Carolina At Chapel Hill Optimized human clotting Factor VIII gene expression cassettes and their use
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
AU2023308137A1 (en) 2022-07-12 2025-01-30 Biotempt B.V. Treating conditions with hypoglycemia associated with hyperinsulinemia.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5492691A (en) * 1977-12-27 1979-07-23 Mitsubishi Chem Ind Ltd Preparation of desoxyribonuclease
JPS566276A (en) * 1979-06-29 1981-01-22 Ricoh Co Ltd Developing device
JPS57146580A (en) * 1981-03-09 1982-09-10 Seikagaku Kogyo Co Ltd Separation and purification of enzyme in human urine
JPS6030512B2 (ja) * 1982-11-26 1985-07-17 科学技術庁長官官房会計課長 制限エンドヌクレア−ゼの調製法

Also Published As

Publication number Publication date
JPS61251700A (ja) 1986-11-08
EP0192392B1 (de) 1991-09-18
DE3681466D1 (de) 1991-10-24
JPH074249B2 (ja) 1995-01-25
EP0192392A3 (en) 1986-11-20
US4761371A (en) 1988-08-02
EP0192392A2 (de) 1986-08-27
CA1341149C (en) 2000-12-05

Similar Documents

Publication Publication Date Title
ATE67504T1 (de) Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten.
DE69026627T2 (de) Antikörperantagonisten gegen humanes interleukin-4
DE68923401T2 (de) Peptide mit T-Zellen-Helfer-Wirksamkeit.
DE3588095D1 (de) Polypeptid, dessen Verfahren zur Herstellung und dieses enthaltende pharmazeutische Zusammensetzung und deren Benutzung
ATE74513T1 (de) Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen.
KR930701601A (ko) O-글리코실화 ifn-알파
CH634039A5 (de) Somatostatinanalogon, sowie verfahren zu seiner herstellung.
DE68914205T2 (de) Zyklische GRF-Analoge.
PT1268530E (pt) Proteínas de fusão do antigénio do core da hepatite b
DE69115917T2 (de) Humane gammainterferonantagonisten
JPH04503602A (ja) Ｉｌ―１生物活性の抑制剤
CN1054772A (zh) 合成多肽
ATE38988T1 (de) Imidazolylphenyl-tetrahydropyridazine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE69333412D1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
JPH09289896A5 (de)
DE3856240D1 (de) Herstellung der p1 proteine und impfstoffe gegen gonorrhöe
EP0228192A3 (de) Renin-hemmende Oligopeptide, deren Herstellung und Anwendung
DE3769563D1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
EP0230242A3 (de) Substituierte 4-Amino-3-hydroxy-buttersäure-Derivate, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
EP0239874A3 (de) Substituierte 4-Amino-3-hydroxybuttersäure-Derivate, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
DE69018702D1 (de) Verfahren zur Herstellung eines Antikaries-Impfstoffes aus Streptococcus mutans und Impfzusammensetzung gegen Karies in Form von Nasentropfen.
DE50301507D1 (de) 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
JPS6150998A (ja) ペンタペプチド化合物の製造方法
EP0310015A3 (de) Renin-hemmende Dipeptide, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
ATE71101T1 (de) Spiro (4,5> decanderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time